Bausch Health resolves patent litigation with Glenmark

Canadian pharmaceutical company Bausch Health and India-based Glenmark Pharmaceuticals have resolved their outstanding IP litigation over Bryhali (halobetasol propionate) lotion.

As part of the settlement, Bausch will grant Glenmark a non-exclusive US licence, effective 2026, to the IP relating to Bryhali lotion.

The lotion, which is used to treat plaque psoriasis in adults, is manufactured by Bausch’s dermatology unit Ortho Dermatologics.

Bausch sued Glenmark in June this year, at the US District Court for the District of New Jersey, after Glenmark filed an Abbreviated New Drug Application (ANDA) for a generic version of Bryhali.

Beginning in 2026 (or earlier under certain circumstances), Glenmark will have the option to market a royalty-free generic version of Bryhali lotion, if it receives approval from the US Food and Drug Administration on its ANDA.

Bausch and Glenmark have agreed to dismiss all litigation relating to the lotion.

US patent number 8,809,307, the final patent on the lotion, expires in 2031, according to a press release from Bausch, published on Friday, December 20.

Bausch said: “Bausch Health remains confident in the strength of the Bryhali lotion patents, and we will continue to vigorously defend its IP.”

Did you enjoy reading this story?  Sign up to our free daily newsletters and get stories sent like this straight to your inbox.